InMed & UBC: Producing Cannabinoids in Labs

“Biosynthesis is nature’s chemistry. Engineering biosynthesis is learning from nature and reproducing them inside a laboratory setting. InMed Pharmaceuticals, in collaboration with my laboratory at UBC is developing a unique platform to produce cannabinoids in the laboratory setting. We are taking the genetics of the cannabis plant, inserting that into microorganisms and that leads to the production of bio identical, high purity high grade cannabinoids. My laboratory has extensive experience in working with a variety of microbials.  The hosts that we ultimately selected for InMed’s proprietary process, E coli, is uniquely suited to producing these molecules. It out performs traditional systems such as yeast and is able to make these molecules at high titers and high productivity. Think of cannabinoid biosynthesis as a collection of lego blocks.

You can make a variety of shapes by piecing together these different pieces of lego. So now what our platform allows us to do, is to piece these different building blocks together, produce unique bio synthetic pathways that ultimately lead to the production of an unprecedented diversity of molecules. This now opens up investigations for therapeutic uses against other diseases that can be used by not just InMed but also its’ collaborating companies and partners. The success of a research team is dependent on the untiring efforts of the researchers involved. Any bio manufacturing process is dependent on three vital pieces. The genetic engineering or strain, the fermentation conditions or the bio process and the downstream or purification processes. We have been working with InMed Pharmaceuticals for nearly three years to get the ideal strain that exhibits the highest productivity. Moving forward, we will be working extensively on bio process engineering to design the ideal process that gives us a competitive advantage and ultimately products that will make a difference to patients lives.” – Dr. Vikramaditya G. Yadav, PhD

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.

For more information on InMed Pharmaceuticals (IN:TSX,IMLFF:OTCQX) please fill out the form below

Request Investor Kit